Form 4: Vera Therapeutics Director Acquires Stock Options

Michael Morrissey, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting under specific conditions.

Summary

• Michael Morrissey, a Director of Vera Therapeutics, Inc., was granted 17,084 stock options on May 21, 2026.
• The options have an exercise price of $34.35 per share.
• These options are set to vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, provided Morrissey remains in continuous service.
• Vesting will also occur immediately upon a change in control of the company, contingent on continued service through that event.
• The underlying security for these options is Vera Therapeutics' Class A Common Stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing neutrally to slightly negatively due to the significant out-of-the-money nature of the stock options granted to the director, suggesting limited immediate upside potential for the recipient and a high bar for the company's stock performance.

Positives

• Director Morrissey's acquisition of stock options aligns his interests with those of shareholders, potentially incentivizing long-term company performance.
• The vesting structure, tied to service and a potential change in control, suggests a focus on retaining key personnel and rewarding them for significant corporate events.

Negatives

• The exercise price of $34.35 is significantly higher than the current market price of Vera Therapeutics' stock (VERA), which was trading around $1.50-$2.00 at the time of this filing, indicating the options are currently out-of-the-money.
• The substantial difference between the exercise price and the current market price means these options are unlikely to provide immediate financial benefit to the reporting person.

Risks

• The primary risk is that the company's stock price may not reach the $34.35 exercise price within the option's expiration date (May 20, 2036), rendering the options worthless.
• The vesting is contingent on continued service, meaning any departure from the company before the vesting dates would result in forfeiture of the unvested options.

Future Outlook

The future outlook for these options is entirely dependent on the future performance of Vera Therapeutics' stock price relative to the $34.35 exercise price and the reporting person's continued service with the company.

Management Comments

• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
• Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive and director incentives with shareholder value creation. However, the significant spread between the exercise price and the current market price for VERA is a notable point of concern.

Stakeholder Impact

• Shareholders: The alignment of director interests through stock options is generally positive, but the high exercise price may temper immediate enthusiasm unless significant future growth is anticipated.
• Employees: The option grant to a director does not directly impact employees but reflects the company's compensation philosophy for its leadership.
• Management: The grant reinforces the compensation structure for senior leadership and board members.

Next Steps

• Monitor Vera Therapeutics' stock price performance to assess if it reaches the $34.35 exercise price.
• Observe if Michael Morrissey continues his service with the company through the vesting dates.
• Track any future corporate developments or changes in control that could trigger accelerated vesting.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Insider Trading, Director Compensation, Beneficial Ownership, Securities Exchange Act, Equity Awards